(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.35%) $0.935
(0.58%) $11.02
(0.14%) $0.800
(0.00%) $92.17
-0.74% INR 1 084.35
Live Chart Being Loaded With Signals
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India...
Stats | |
---|---|
Tagesvolumen | 63 966.00 |
Durchschnittsvolumen | 240 658 |
Marktkapitalisierung | 55.00B |
EPS | INR0 ( 2024-02-09 ) |
Nächstes Ertragsdatum | ( INR0 ) 2024-05-07 |
Last Dividend | INR3.00 ( 2012-09-13 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 38.03 |
ATR14 | INR0.974 (0.09%) |
Volumen Korrelation
Orchid Pharma Limited Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Orchid Pharma Limited Korrelation - Währung/Rohstoff
Orchid Pharma Limited Finanzdaten
Annual | 2022 |
Umsatz: | INR6.66B |
Bruttogewinn: | INR2.81B (42.24 %) |
EPS: | INR11.35 |
FY | 2022 |
Umsatz: | INR6.66B |
Bruttogewinn: | INR2.81B (42.24 %) |
EPS: | INR11.35 |
FY | 2022 |
Umsatz: | INR5.60B |
Bruttogewinn: | INR2.33B (41.69 %) |
EPS: | INR-0.350 |
FY | 2021 |
Umsatz: | INR4.50B |
Bruttogewinn: | INR2.10B (46.68 %) |
EPS: | INR-28.55 |
Financial Reports:
No articles found.
Orchid Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR2.67 | 2002-07-16 |
Last Dividend | INR3.00 | 2012-09-13 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | INR36.67 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.66 | -- |
Div. Sustainability Score | 4.51 | |
Div.Growth Potential Score | 2.49 | |
Div. Directional Score | 3.50 | -- |
Year | Amount | Yield |
---|---|---|
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SCI.NS | Dividend Junior | 2023-09-01 | Sporadic | 22 | 0.25% | |
MALLCOM.NS | Dividend Junior | 2023-09-04 | Annually | 3 | 0.20% | |
GOKEX.NS | Dividend Junior | 2023-09-13 | Sporadic | 20 | 0.07% | |
AUTOAXLES.NS | Dividend Junior | 2023-07-27 | Annually | 22 | 0.72% | |
TRENT.NS | Dividend Junior | 2023-05-25 | Annually | 21 | 0.10% | |
PIDILITIND.NS | Dividend Junior | 2023-07-27 | Annually | 23 | 0.29% | |
JINDRILL.NS | Dividend Junior | 2023-08-14 | Annually | 18 | 0.23% | |
DELTACORP.NS | Dividend Junior | 2023-07-07 | Annually | 17 | 0.39% | |
SMLT.NS | Dividend Knight | 2023-08-09 | Semi-Annually | 3 | 0.64% | |
MIDHANI.NS | Dividend Junior | 2023-09-22 | Semi-Annually | 7 | 1.04% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.145 | 1.500 | 7.10 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.131 | 1.500 | 9.65 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 5.21 | 1.000 | 9.18 | 9.18 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.63 | 2.00 | 5.79 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.63 | 2.00 | 3.69 | 7.37 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.415 | 1.000 | 6.42 | 6.42 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.131 | 1.000 | 9.38 | 9.38 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 46.70 | 1.000 | 5.38 | 0 | [1 - 100] |
returnOnEquityTTM | 0.131 | 2.50 | 9.78 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.63 | 2.00 | 5.79 | 7.37 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.63 | 2.00 | 5.79 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.243 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0789 | 1.000 | -0.528 | 0 | [0.1 - 0.5] |
Total Score | 2.49 |
Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company's multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. In addition, the company provides liaising support to customers in regulatory, pharma covigilance, testing and release, retention of samples, service providers, and business development. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited is a subsidiary of Dhanuka Laboratories Limited.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.